141 related articles for article (PubMed ID: 8039111)
1. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer.
Rushing DA; Raber SR; Rodvold KA; Piscitelli SC; Plank GS; Tewksbury DA
Cancer; 1994 Aug; 74(3):834-41. PubMed ID: 8039111
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer.
Piscitelli SC; Rodvold KA; Rushing DA; Tewksbury DA
Clin Pharmacol Ther; 1993 May; 53(5):555-61. PubMed ID: 8387903
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy.
Wilson WH; Jamis-Dow C; Bryant G; Balis FM; Klecker RW; Bates SE; Chabner BA; Steinberg SM; Kohler DR; Wittes RE
J Clin Oncol; 1995 Aug; 13(8):1985-94. PubMed ID: 7636539
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer.
Swenson CE; Bolcsak LE; Batist G; Guthrie TH; Tkaczuk KH; Boxenbaum H; Welles L; Chow SC; Bhamra R; Chaikin P
Anticancer Drugs; 2003 Mar; 14(3):239-46. PubMed ID: 12634619
[TBL] [Abstract][Full Text] [Related]
5. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.
Lum BL; Kaubisch S; Fisher GA; Brown BW; Sikic BI
Cancer Chemother Pharmacol; 2000; 45(4):305-11. PubMed ID: 10755319
[TBL] [Abstract][Full Text] [Related]
6. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.
Erlichman C; Moore M; Thiessen JJ; Kerr IG; Walker S; Goodman P; Bjarnason G; DeAngelis C; Bunting P
Cancer Res; 1993 Oct; 53(20):4837-42. PubMed ID: 8402670
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.
Bartlett NL; Lum BL; Fisher GA; Brophy NA; Ehsan MN; Halsey J; Sikic BI
J Clin Oncol; 1994 Apr; 12(4):835-42. PubMed ID: 8151326
[TBL] [Abstract][Full Text] [Related]
8. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.
Hong WK; Nicaise C; Lawson R; Maroun JA; Comis R; Speer J; Luedke D; Hurtubise M; Lanzotti V; Goodlow J
J Clin Oncol; 1989 Apr; 7(4):450-6. PubMed ID: 2538577
[TBL] [Abstract][Full Text] [Related]
9. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.
Lum BL; Kaubisch S; Yahanda AM; Adler KM; Jew L; Ehsan MN; Brophy NA; Halsey J; Gosland MP; Sikic BI
J Clin Oncol; 1992 Oct; 10(10):1635-42. PubMed ID: 1403041
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G
Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
[TBL] [Abstract][Full Text] [Related]
11. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
Sonneveld P; Marie JP; Huisman C; Vekhoff A; Schoester M; Faussat AM; van Kapel J; Groenewegen A; Charnick S; Zittoun R; Löwenberg B
Leukemia; 1996 Nov; 10(11):1741-50. PubMed ID: 8892677
[TBL] [Abstract][Full Text] [Related]
12. The disposition of doxorubicin on repeated dosing.
Rushing DA; Piscitelli SC; Rodvold KA; Tewksbury DA
J Clin Pharmacol; 1993 Aug; 33(8):698-702. PubMed ID: 8408728
[TBL] [Abstract][Full Text] [Related]
13. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.
Johnson DH; Einhorn LH; Birch R; Vollmer R; Perez C; Krauss S; Omura G; Greco FA
J Clin Oncol; 1987 Nov; 5(11):1731-8. PubMed ID: 2824707
[TBL] [Abstract][Full Text] [Related]
14. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations.
Lum BL; Fisher GA; Brophy NA; Yahanda AM; Adler KM; Kaubisch S; Halsey J; Sikic BI
Cancer; 1993 Dec; 72(11 Suppl):3502-14. PubMed ID: 7902206
[TBL] [Abstract][Full Text] [Related]
15. Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer.
Ohnoshi T; Hiraki S; Ueoka H; Kiura K; Kamei H; Horiguchi T; Kodani T; Maeda T; Tabata M; Shibayama T
Cancer; 1993 Sep; 72(5):1597-601. PubMed ID: 8394202
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin clearance in the obese.
Rodvold KA; Rushing DA; Tewksbury DA
J Clin Oncol; 1988 Aug; 6(8):1321-7. PubMed ID: 3411343
[TBL] [Abstract][Full Text] [Related]
17. A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors.
Planting AS; Sonneveld P; van der Gaast A; Sparreboom A; van der Burg ME; Luyten GP; de Leeuw K; de Boer-Dennert M; Wissel PS; Jewell RC; Paul EM; Purvis NB; Verweij J
Cancer Chemother Pharmacol; 2005 Jan; 55(1):91-9. PubMed ID: 15565444
[TBL] [Abstract][Full Text] [Related]
18. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
[TBL] [Abstract][Full Text] [Related]
19. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group.
Work E; Nielsen OS; Bentzen SM; Fode K; Palshof T
J Clin Oncol; 1997 Sep; 15(9):3030-7. PubMed ID: 9294465
[TBL] [Abstract][Full Text] [Related]
20. Effects of amiodarone, cyclosporin A, and PSC 833 on the cytotoxicity of mitoxantrone, doxorubicin, and vincristine in non-P-glycoprotein human small cell lung cancer cell lines.
van der Graaf WT; de Vries EG; Timmer-Bosscha H; Meersma GJ; Mesander G; Vellenga E; Mulder NH
Cancer Res; 1994 Oct; 54(20):5368-73. PubMed ID: 7923167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]